The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price increase of 8.60%. However, over the past six months, we’ve seen a weaker performance of 14.88%. The price of SUPN fallen by 2.01% over the last 30 days. And in the last five days, it has fallen by -6.24%.
The stock market performance of Supernus Pharmaceuticals Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $39.09 on 04/21/23, while the lowest price during the same time frame was $21.99, recorded on 10/27/23.
52-week price history of SUPN Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Supernus Pharmaceuticals Inc’s current trading price is -19.60% away from its 52-week high, while its distance from the 52-week low is 42.93%. The stock’s price range for this period has been between $21.99 and $39.09. The Healthcare sector company’s shares saw a trading volume of about 0.79 million for the day, which was higher than the average daily volume of 0.39 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Supernus Pharmaceuticals Inc (SUPN) has experienced a quarterly rise of 14.58% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.72B and boasts a workforce of 652 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 29.30, with a change in price of +4.78. Similarly, Supernus Pharmaceuticals Inc recorded 375,049 in trading volume during the last 100 days, posting a change of +17.94%.
SUPN’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for SUPN stands at 0.05. Similarly, the long-term debt-to-equity ratio is also 0.04.
SUPN Stock Stochastic Average
As of today, the raw stochastic average of Supernus Pharmaceuticals Inc over the past 50 days is 56.25%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 17.49%. Additionally, the Stochastic %K and %D values for the company were 43.58% and 55.19%, respectively, over the past 20 days.
